Current problems in cancer. Case reports最新文献_第2页

A case of opsoclonus-myoclonus syndrome associated with breast cancer

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-12-19 DOI: 10.1016/j.cpccr.2024.100346

Sebastian Mohar , Naomi Fujioka , Todd Tuttle , Bruce Trautman , Emilian Racila , Jianling Yuan , Sean J. Pittock , David A. Potter

引用次数: 0

Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-12-18 DOI: 10.1016/j.cpccr.2024.100345

Bilal Kazi , Imaan Rumani , Marzooka Nazim Chishti Kazi , Prashant Manohar Gaikwad

引用次数: 0

Pleural mesothelioma: Long-term progression-free survival with Tumor Treating Fields (TTFields) therapy case reports

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-30 DOI: 10.1016/j.cpccr.2024.100342

Giovanni Luca Ceresoli , Laura Mannarino , Lara Paracchini , Federica Grosso

引用次数: 0

Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-28 DOI: 10.1016/j.cpccr.2024.100338

Anh Tuan Pham , Thang Huu Nguyen , Thai Hong Le , Toan Khanh Phan , Anh Phuong Nguyen , Ngoc Minh Le , Thao Thu Vu

{"title":"Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report","authors":"Anh Tuan Pham , Thang Huu Nguyen , Thai Hong Le , Toan Khanh Phan , Anh Phuong Nguyen , Ngoc Minh Le , Thao Thu Vu","doi":"10.1016/j.cpccr.2024.100338","DOIUrl":"10.1016/j.cpccr.2024.100338","url":null,"abstract":"<div><div>Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) typically have an unfavorable prognosis, with a median survival of only 6 to 15 months in most studies. In cases other than local relapse or oligometastases, systemic therapy plays the dominant role. The choice of regimen is influenced by multiple clinical factors, including patient comorbidities, performance status, previous therapy, and pathologic features. We present a case of PD-L1 (programmed death-ligand 1)-negative metastatic hypopharyngeal cancer successfully treated with pembrolizumab monotherapy, followed by cetuximab combined with chemotherapy. Remarkably, the patient currently remains in good health, with no signs of disease on imaging at 35 months after diagnosis. We emphasized the importance of a well-devised treatment strategy, as well as the significant synergistic effects of the sequence in which the cetuximab-based regimen follows immune checkpoint inhibitors.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100338"},"PeriodicalIF":0.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review BRCA1/2致病变异患者的her2阳性乳腺癌：病例系列和文献综述

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-25 DOI: 10.1016/j.cpccr.2024.100335

Pujita Munnangi , Polly Ann Niravath , Jenny C Chang , Kai Sun

{"title":"HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review","authors":"Pujita Munnangi , Polly Ann Niravath , Jenny C Chang , Kai Sun","doi":"10.1016/j.cpccr.2024.100335","DOIUrl":"10.1016/j.cpccr.2024.100335","url":null,"abstract":"<div><h3>Research purpose</h3><div>HER2-positive breast cancers are uncommonly reported in patients with <em>BRCA1/2</em> pathogenic variants. The purpose of this case series is to describe three patients with <em>BRCA1/2</em> pathogenic variants who developed HER2-positive breast cancers and their treatment courses along with that of a patient from a previously published case report, and describe existing literature exploring associations between HER2<em>-</em>positive breast cancers and germline variants.</div></div><div><h3>Key findings</h3><div>HER2-positive breast cancer is uncommon in patients with <em>BRCA1/2</em> pathogenic variants. The patients in our case series had hormone receptor positive and HER2-positive breast cancers. HER2 FISH was commonly utilized for the confirmation of HER2 status in our case series. All patients responded well to HER-2 directed therapies.</div></div><div><h3>Conclusions & clinical implications</h3><div>While the interactions between <em>BRCA1/2</em> pathogenic variants and the HER2 pathway are unclear, our case series and existing literature suggest that HER2-positive breast cancer occurrence is mainly HER2 oncogenic pathway driven. But the interplay between the DNA repair pathway and the HER2 oncogenic pathway could impact HER2 gene expression and play a potentially important role in treatment resistance and therapy options. Combining olaparib and trastuzumab could be considered for off-label use in patients with <em>BRCA 1/2</em> mutations with HER2-positive breast cancer who failed HER2-targeted therapy.</div></div><div><h3>Limitations</h3><div>This study is limited by small sample size (<em>n</em> = 4). Since it is a retrospective study, it is also limited by selection bias, lack of control group for comparison purposes, and potential influence of confounding variables.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100335"},"PeriodicalIF":0.2,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature 全经维甲酸恢复达拉单抗难治性多发性骨髓瘤患者对达拉单抗的敏感性：一个病例报告和文献回顾

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-23 DOI: 10.1016/j.cpccr.2024.100336

Noa Biran , David H. Vesole , Harsh Parmar , Pooja Phull , Susan Kumka , Kimberly Doucette , Joshua Zenreich , Bianca DeAgresta , Alexandra Della Pia , Lisa Biamonte , Martha Campanaro , Trina McClendon , Samanta BaboolallAracena , Palka Anand , Adolfo Aleman , Monique Pace , Genevieve Breeze , Kristin Ivanovski , Marie Layton , David S. Siegel

引用次数: 0

Activity of pemetrexed in recurrent, metastatic sacral chordoma: A case report 培美曲塞治疗复发性、转移性骶脊索瘤1例

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-22 DOI: 10.1016/j.cpccr.2024.100340

Dominique G. Celestino , Lara E. Davis , Santosh Kesari

{"title":"Activity of pemetrexed in recurrent, metastatic sacral chordoma: A case report","authors":"Dominique G. Celestino , Lara E. Davis , Santosh Kesari","doi":"10.1016/j.cpccr.2024.100340","DOIUrl":"10.1016/j.cpccr.2024.100340","url":null,"abstract":"<div><div>Chordomas are a rare slow growing tumor with a high recurrence rate that originate from residual embryonic notochord cells, primarily affecting the axial skeleton. Currently limited treatment options exist beyond surgery and radiation, and systemic chemotherapy has shown limited efficacy. The majority of chordomas exhibit negative thymidylate synthase (TS) expression, implying a potential responsiveness to the antifolate agent pemetrexed. We present a case report of a 78-year-old patient with recurrent, metastatic sacral chordoma who showed clinical and radiological improvement with pemetrexed treatment. The patient received 12 cycles of pemetrexed which resulted in a decrease in the size of liver and lung lesions. Moreover, the patient experienced resolution of debilitating symptoms, including right leg weakness, and unsteady gait. This case report highlights the use of pemetrexed as a therapeutic option for recurrent and metastatic chordoma. Further research is warranted to explore the optimal use of pemetrexed in chordoma management and identify predictive biomarkers for treatment response.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100340"},"PeriodicalIF":0.2,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-22 DOI: 10.1016/j.cpccr.2024.100334

Martin Dietrich , Michel Velez

引用次数: 0

Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment 对肝功能严重受损的转移性乳腺癌患者使用曲妥珠单抗德鲁司坦

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-22 DOI: 10.1016/j.cpccr.2024.100337

Laura Sun , Gaybrielle Moore , Annalise Labatut , Jane Meisel , Kevin Kalinsky , Kristina Byers

引用次数: 0

Cytokine release syndrome in non- small cell lung cancer patient receiving immune checkpoint inhibitors: A case report 接受免疫检查点抑制剂的非小细胞肺癌患者的细胞因子释放综合征：1例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-22 DOI: 10.1016/j.cpccr.2024.100339

Ana Geltar , Assist Urska Janzic

{"title":"Cytokine release syndrome in non- small cell lung cancer patient receiving immune checkpoint inhibitors: A case report","authors":"Ana Geltar , Assist Urska Janzic","doi":"10.1016/j.cpccr.2024.100339","DOIUrl":"10.1016/j.cpccr.2024.100339","url":null,"abstract":"<div><div>Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy (CAR-T) but has rarely been reported following therapy with immune checkpoint inhibitors (ICI).</div><div>We present a clinical case of severe CRS after ICI therapy for advanced non-small-cell lung cancer (NSCLC). After the third cycle of ipilimumab and nivolumab the patient presented with fever, hypotension and somnolence, leading to acute respiratory failure, acute kidney and hepatic failure, capillary leak syndrome, requiring ICU (intensive care unit) care. She recovered after receiving tocilizumab and steroid therapy.</div><div>Subsequently, we found 17 clinical cases of advanced NSCLC patients in peer review, experiencing CRS as an adverse event of treatment with ICI. We review those cases in detail and compare the similarities and outcomes.</div><div>Conclusion: CRS is a serious, life-threatening complication that is rare after ICI therapy for solid cancers but becoming increasingly frequent since ICI therapies are broadening indications. When presented with clinical symptoms, considering CRS is crucial, as early recognition is key to timely intervention and favorable outcome for the patient.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100339"},"PeriodicalIF":0.2,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0